Stock Events

Cabaletta Bio 

M$206.1
0
+M$0+0% Wednesday 19:17

Statistics

Day High
202.11
Day Low
202.11
52W High
418.23
52W Low
202.11
Volume
2,400
Avg. Volume
254
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

9MayConfirmed
Q4 2023
Q1 2024
-8.09
-7.58
-7.08
-6.57
Expected EPS
-8.08722104904
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CABA.MX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.69B
CRISPR Therapeutics is involved in gene editing, a technology that can be applied to the development of treatments for autoimmune diseases, directly competing with Cabaletta Bio's focus on engineered T cell therapies.
Intellia Therapeutics
NTLA
Mkt Cap2.4B
Intellia Therapeutics is a leading developer of CRISPR gene editing therapies, potentially targeting similar autoimmune and other diseases as Cabaletta Bio.
Editas Medicine
EDIT
Mkt Cap463M
Editas Medicine operates in the CRISPR gene editing space, focusing on delivering transformative genetic treatments that could overlap with Cabaletta Bio's therapeutic areas.
Allogene Therapeutics
ALLO
Mkt Cap430.55M
Allogene Therapeutics focuses on allogeneic CAR T cell therapies, which could be used in similar applications to Cabaletta Bio's autologous T cell therapies, making them direct competitors.
Adaptimmune Therapeutics
ADAP
Mkt Cap162.39M
Adaptimmune Therapeutics specializes in T-cell receptor (TCR) engineered T cell therapies for cancer, but its technology could be adapted to target autoimmune diseases, competing with Cabaletta Bio.
Bluebird bio
BLUE
Mkt Cap105.66M
bluebird bio's gene therapy approach, including its work in CAR T and TCR therapies, positions it as a competitor in the advanced therapy medicinal products (ATMPs) space, including potential overlaps with Cabaletta's focus areas.
Fate Therapeutics
FATE
Mkt Cap400.69M
Fate Therapeutics is developing programmed cellular immunotherapies, including NK and T-cell therapies, which could compete with Cabaletta Bio's engineered T cell approaches for autoimmune diseases.
Sangamo Therapeutics
SGMO
Mkt Cap123.51M
Sangamo Therapeutics' gene editing technology, including zinc finger nuclease (ZFN) technology, targets genetic conditions that could overlap with Cabaletta Bio's therapeutic areas, making them competitors.
Biomarin Pharmaceutical
BMRN
Mkt Cap14.34B
BioMarin Pharmaceutical focuses on enzyme replacement therapies but is expanding into gene therapies, which could potentially compete with Cabaletta Bio's approach to treating autoimmune diseases.
Pfizer
PFE
Mkt Cap163.65B
Pfizer, with its broad interest in biopharmaceuticals, including investments in gene therapy and immunology, represents a potential competitor across multiple areas of Cabaletta Bio's interest due to its scale and breadth of research.

About

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Show more...
CEO
Employees
118
Country
US
ISIN
US12674W1099

Listings